Healthcare Industry News: kidney disease
News Release - July 15, 2010
Amgen Appoints Jonathan M. Peacock Executive Vice President and Chief Financial Officer
THOUSAND OAKS, Calif., July 15 (Healthcare Sales & Marketing Network) -- Amgen (Nasdaq:AMGN ) today announced the appointment effective Sept. 1 of Jonathan M. Peacock as chief financial officer (CFO). He will be responsible for Amgen's finance and investor relations operations. Peacock will report to Kevin W. Sharer, Amgen's chairman and chief executive officer, and will succeed Michael A. Kelly, who served as acting CFO since May 2010.Previously, Peacock was a partner at McKinsey and Company, where he was co-leader of the European corporate finance practice working in the consulting firm's Amsterdam, Zurich and London offices. He also was a partner at Price Waterhouse in New York and London. He has an MA degree in Economics from the University of St. Andrews in Scotland and is a chartered accountant.
"I am delighted to have a leader of Jonathan's talent, vision and international experience join Amgen at a time when we are expanding globally," said Sharer.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.
Source: Amgen
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
Related News Items
EVOQ Therapeutics Announces a License And Collaboration Agreement with AmgenUpdate On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
Amgen's Sotorasib Granted Breakthrough Therapy Designation for Advanced or Metastatic Non-Small Cell Lung Cancer Patients with KRAS G12C Mutation
